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ABSTRACT
Colorectal cancer (CRC) is the third most common cancer in the world. More than half of all affected 
patients develop liver metastases during the course of the disease, and over half experience recurrence 
despite radical primary surgery. Transketolase-like protein 1 (TKTL1) is a key enzyme in the glucose 
metabolism of cancer cells, and its expression in tumor tissue was previously shown to indicate a poor 
prognosis in colorectal cancer. In this study, we investigated the prognostic significance of TKTL1 in 111 
patients with surgically resected colorectal liver metastases, with a minimum follow-up time of 10.3 years. 
TKTL1 expression was examined in tissue samples of both primary tumors and liver metastases, and 
compared to clinicopathological parameters, disease-free survival, and overall survival. We show that 
a high expression of TKTL1 in primary tumor tissue associated with poor disease-free survival in patients 
with synchronous liver metastases (P = .026, Kaplan-Meier log-rank test), but with better disease-free 
survival in patients with metachronous metastases, although not statistically significantly (P = .073). We 
found similar tendencies for TKTL1 expression in liver metastases. Thus, TKTL1 could serve as a candidate 
marker to identify patients who benefit from liver resection or who need more aggressive perioperative 
chemotherapy.
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Introduction
Colorectal cancer (CRC) is the third most common cancer in 
the world with over 1.8 million new cases diagnosed annually 
and causing around 881 000 deaths every year.1 More than 50% 
of patients with CRC will eventually develop liver metastases. 
Resection of liver metastases in CRC is recommended when R0 
resection is technically possible, leaving a minimum of 30% of 
the liver remnant. Chemotherapy should be combined to resec-
tion perioperatively in most cases, whereby even initially non- 
resectable metastases (that is, borderline resectable cases) may 
become resectable following chemotherapy. However, about 
half of all patients develop recurrent disease within 3 years 
following liver resection.2 The prognosis of patients with 
stage IIIc to IV disease has improved in recent decades due 
to more aggressive operative treatment and more precise che-
motherapy, where overall survival at 5 years now reaches over 
50% following curative-intent liver resection.3,4
Glucose metabolism in cancer cells differs from that in 
normal cells. Transketolase-like protein 1 (TKTL1), an isoform 
of transketolase, is one of the key factors in catalyzing the non- 
oxidative part of the pentose phosphate pathway in cancer 
cells.5 Previously, we showed that TKTL1 serves as 
a prognostic marker in colorectal cancer, such that patients 
with a high tumor expression of TKTL1 had a poor prognosis.6 
Here, we aimed to investigate whether TKTL1 serves as 
a similar marker of poor prognosis among patients with color-
ectal cancer metastasized to the liver.
Results
Patient characteristics
Between September 1988 and June 2007, colorectal primary 
tumors were operated on 111 patients, 64 (58%) of whom were 
men (Table 1). The liver resections were performed between 
August 1997 and July 2007. At the time of the liver resection, 53 
(48%) patients were over 65 years old. The primary tumor was 
located in the rectum in 48 (43%), in the left colon or recto-
sigmoid junction in 44 (40%), and in the right or transversal 
colon in 19 (17%) cases. The median time from the operation 
on the primary tumor to the liver resection was 11.1 months 
(range 0.7 months–10.3 years).
Of the rectal cancer patients (N = 48), 8 (17%) received 
neoadjuvant chemoradiotherapy before the operation on the 
primary tumor (data missing from 10 (21%) patients). Half of 
all patients (N = 53; 48%) received adjuvant chemotherapy 
after the operation on the primary tumor (data missing from 
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26 (23%) patients). Before and after the liver resection, 68 
(61%) patients received neoadjuvant chemotherapy (data miss-
ing from 4 (4%) patients), and 85 (77%) adjuvant chemother-
apy (data missing from 9 (8%) patients) (Table 2).
Median survival time following liver resection was 5.7 years 
(2.4 months–19.3 years). Overall survival at 5 years was 60% (67/ 
111) and at 10 years was 37% (41/111). The median follow-up 
time for living patients was 14.1 years (range 10.3–19.3 years).
During follow-up, 80 patients (72%) experienced recur-
rence, 17 of whom were already diagnosed within 3 months, 
53 within 3 years, and 10 later. The most common site for 
recurrence was the liver (57%); new metastases were diagnosed 
in other sites in 43% of cases.
TKTL1 expression in tissue samples
Of the 81 primary tumor samples, none were scored as 
negative, 8 (10%) as weakly positive, 48 (59%) as moder-
ately positive, and 25 (31%) as strongly positive. Among the 
90 liver metastases samples, 5 (6%) were scored as negative, 
15 (17%) as weakly positive, 42 (47%) as moderately posi-
tive, 27 (30%) as strongly positive, and one sample was 
excluded from further analysis. We found no significant 
correlation between the TKTL1 expression of patients’ 
primary tumor and liver metastases using the Spearman’s 
rank correlation test (data not shown).
Table 1.
Patient characteristics N (%) or median (min.-max.)
Synchronous1 CLM2, N = 66 Metachronous CLM, N = 45
Sex
Male 38 (57.6%) 26 (57.8%)
Female 28 (42.4%) 19 (42.2%)
Age
At operation on the primary tumor 62.9 years (35.6–80.5) 62.4 years (45.8–79.8)
At first liver resection 63.4 years (36.3–80.8) 65.9 years (46.9–81.5)
>65 years at primary operation 25 (37.9%) 20 (44.4%)
>65 years at liver resection 29 (43.9%) 24 (53.3%)
Location of the primary tumor
Rectum 29 (43.9%) 19 (42.2%)
Left colon or rectosigmoid junction 24 (36.4%) 20 (44.4%)
Right or transversal colon 13 (19.7%) 6 (13.3%)
T1–2 7 (10.6%) 7 (15.6%)
T3–4 55 (83.3%) 30 (66.7%)
Missing data 4 (6.1%) 8 (17.8%)
N0 15 (22.7%) 15 (33.3%)
N1 26 (39.4%) 15 (33.3%)
N2 21 (31.8%) 7 (15.6%)
Missing data 4 (6.1%) 8 (17.8%)
Liver metastases
Number of liver metastases 2 (0–8) 1 (1–7)
Diameter of the largest liver metastasis 2.3 cm (0.0–9.0) 2.5 cm (0.7–9.0)
Resection margins
R0 (resection margin histologically free) 61 (92.4%) 41 (91.1%)
R1 (histological neoplastic infiltration)  
Missing data
5 (7.6%) 
0 (0.0%)
3 (6.7%) 
1 (2.2%)
Recurrences after liver resection 50 (75.8%) 30 (66.7%)
Recurrence within 3 months 12 (18.2%) 6 (13.3%)
Recurrence between 3 months and 3 years 34 (51.5%) 18 (40.0%)
Recurrence after 3 years 4 (6.1%) 6 (13.3%)
Time to recurrence 9.9 months (1.2–66.3) 14.2 months (1.8–112.7)
Site of recurrence
Liver 26/50 (52.0%) 18/30 (60.0%)
Other 22/50 (44.0%) 10/30 (33.3%)
Missing data 2/50 (4.0%) 2/30 (6.7%)
Overall survival time 5.3 years (0.6–17.4) 6.5 years (0.2–19.3)
10–year overall survival 22 (33.3%) 19 (42.2%)
1The liver metastases were considered synchronous, if they were diagnosed within 6 months after the operation on the primary tumor. 
2Colorectal liver metastases.
Table 2. Characteristics of the patients’ neoadjuvant and adjuvant treatment in 
conjunction with liver resection.
N (%)
Synchronous1 CLM, 
N = 66
Metachronous CLM, 
N = 45
Neoadjuvant chemotherapy before 
liver resection 
Fluoropyrimidine-based 
Oxaliplatin-based 
Irinotecan-based 
Bevacizumab/EGFRI2 included 
Other/type not known 
No chemotherapy 
Data missing
49/66 (74.2%) 
13 (19.7%) 
10 (15.2%) 
8 (12.1%) 
13 (19.7%) 
5 (7.6%) 
16 (24.2%) 
1 (1.5%)
19/45 (42.2%) 
8 (17.8%) 
8 (17.8%) 
3 (6.7%) 
23 (51.1%) 
3 (6.7%)
Adjuvant chemotherapy after liver 
resection 
Fluoropyrimidine-based 
Oxaliplatin-based 
Irinotecan-based 
Bevacizumab/EGFRI included 
Other/type not known 
No chemotherapy 
Data missing
55/66 (83.3%) 
10 (15.2%) 
15 (22.7%) 
9 (13.6%) 
13 (19.7%) 
8 (12.1%) 
6 (9.1%) 
5 (7.6%)
30/45 (66.7%) 
12 (26.7%) 
12 (26.7%) 
3 (6.7%) 
1 (2.2%) 
2 (4.4%) 
11 (24.4%) 
4 (8.9%)
1The liver metastases were considered synchronous, if they were diagnosed 
within 6 months after the operation on the primary tumor. 
2Epidermal growth factor receptor inhibitor.
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For the statistical analyses, the samples with negative, mild 
or moderate expressions were grouped as “low” and those with 
a strong expression as “high”.
Survival analyses
Across the entire cohort, we found no statistically significant 
relationship between TKTL1 expression in either primary 
tumors or liver metastases and 1) disease-free survival (DFS) 
or 2) overall survival (OS) in the Kaplan-Meier log rank or the 
Cox regression analysis. We also found no association between 
these when patients were divided into subgroups according to 
the primary tumor location, that is, left- and right-sided colon 
and rectal cancer.
Comparison between synchronous and metachronous 
disease
Patients presenting with synchronous liver metastases and 
a high TKTL1 expression in primary tumors exhibited shorter 
DFS compared to patients with a low expression (P = .030, 
hazard ratio (HR) 2.14, 95% confidence interval (CI) 1.08–4.25; 
Figure 1(a)). A high TKTL1 expression in the liver metastases 
did not associate with a shorter DFS (P = .081, Kaplan-Meier 
log-rank test; Figure 2(a)). However, only 12% (2/17) of the 
patients with a high expression in the liver metastases were 
alive without recurrence 3 years following liver resection com-
pared to 30% (10/33) of those with a low expression. This same 
association was seen for OS, although this was not statistically 
significant.
In metachronous disease, patients with a high TKTL1 
expression in the primary tumors exhibited a better DFS, 
although this finding was not statistically significant 
(P = .084, HR 0.41, 95% CI 0.15–1.13; Figure 1(b)). A high 
TKTL1 expression in the liver metastases did not associate with 
a better DFS (P = .129, Kaplan-Meier log-rank test; Figure 2 
(b)), although 70% (7/10) of patients with a high expression 
were alive without recurrence 3 years later compared to 32% 
(9/28) of those with a low expression. In OS, we found no 
significant differences between the high and low expression 
groups (data not shown).
When we analyzed only those patients with a high TKTL1 
expression in their primary tumors (N = 25), those with syn-
chronous liver metastases had a significantly worse DFS than 
those with metachronous liver metastases (P = .005, HR 4.66, 
95% CI 1.57–13.8; Figure 3(a)). This was also evident in 
patients with a high TKTL1 expression in the liver metastases 
(N = 27); DFS was worse among those with synchronous 
metastases compared to metachronous metastases (P = .019, 
HR 3.55, 95% CI 1.23–10.2; Figure 3(b). We found no similar 
differences for subgroups of patients with a low TKTL1 expres-
sion in the primary tumors or liver metastases.
When comparing the subgroups of patients who received 
adjuvant chemotherapy with those who did not and further 
dividing them into groups based on TKTL1 score, we found no 
statistically significant differences in overall survival. In 
patients who had synchronous disease and received adjuvant 
chemotherapy after liver resection, a high TKTL1 expression in 
primary tumors or in liver metastases associated with a worse 
DFS than low TKTL1 expression (P = .015 and P = .027, 
respectively). On the contrary, in patients who had metachro-
nous disease and received adjuvant chemotherapy, a high 
TKTL1 expression in liver metastases associated with a better 
DFS (P = .034).
Discussion
In our patient cohort, a high TKTL1 expression served as 
a marker of poor prognosis in patients with synchronous 
liver metastases of colorectal cancer. By contrast, in patients 
with metachronous liver metastases, a high expression in both 
the primary tumor and liver metastases indicated a better 
Figure 1. TKTL1 expression in primary CRC tumors in relation to disease-free 
survival. Patients with (a) synchronous liver metastases (N = 50) and (b) meta-
chronous liver metastases (N = 31).
Figure 2. TKTL1 expression in liver metastases of CRC in relation to disease-free 
survival. Patients with (a) synchronous liver metastases (N = 50) and (b) meta-
chronous liver metastases (N = 39).
Figure 3. Patients with a high TKTL1 expression in (a) primary CRC tumors (N = 25) 
and (b) liver metastases (N = 27). Synchronous and metachronous disease in 
relation to disease-free survival.
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prognosis. In other cancers, a high TKTL1 expression was 
shown to indicate a poor prognosis.7–11 Thus, our results 
provide a new dimension to this marker.
Previous studies demonstrated that metastatic colorectal can-
cer patients with synchronous liver metastases have a worse 
prognosis than patients with metachronous metastases.12 This 
was apparent in our study as well: only 29% (19/66) of all 
patients with synchronous liver metastases were alive without 
recurrence 3 years after liver resection, whereas that percentage 
increased to 44% (20/45) for patients with metachronous disease. 
However, OS at 10 years after liver resection was 33% (22/66) 
among patients with synchronous metastases and 42% (19/45) 
among those with metachronous metastases, indicating that 
patients with recurrent disease can also live several years thanks 
to current surgical and oncological treatments.
In our previous study of TKTL1 in colorectal cancer, we 
showed that patients with a high TKTL1 expression in the 
primary tumors exhibited a worse prognosis compared to 
those with a low expression.6 Most patients, however, had 
local or locally advanced disease, and only 190 (23%) had 
stage IV CRC at the time of diagnosis. In the current study, 
all patients had advanced disease.
When we analyzed DFS in patients with a low TKTL1 
expression, we observed no obvious difference between 
patients with synchronous and metachronous disease. 
Instead, when the TKTL1 expression was high, the difference 
became apparent. When the TKTL1 score was analyzed from 
the primary tumors, DFS at 3 years reached only 7% (1/14) for 
patients with a high TKTL1 score and synchronous disease; 
among those with a high TKTL1 score and metachronous 
disease, DFS reached 73% (8/11). The same difference was 
seen for TKTL1 expression in liver metastases. These findings 
suggest that synchronous and metachronous mCRC are differ-
ent types of disease, possibly explaining the reverse prognostic 
significance of TKTL1.
In a previous study by Diaz-Moralli et al., the expression of 
TKTL1 in primary colorectal tumors was studied in both local 
and metastatic disease. They noticed that in CRC stages 
I through III TKTL1 expression increased progressively, but 
in stage IV there was a strong decrease in expression.13 
A similar pattern was also found in the incidence of mutated 
RAS in CRC. Thus, Diaz-Moralli et al. argued that RAS muta-
tions might lead to the activation of TKTL1 expression, possi-
bly permitting carcinogenic cells to consume glucose in the 
absence of oxygen, produce lactate, and acidify their micro-
environment, thereby increasing the invasiveness of cancer. 
Based on those findings, it seems that the expression pattern 
of TKTL1 changes when colorectal cancer becomes metastatic. 
This supports our findings concerning the differences between 
synchronous and metachronous disease. When patients are 
diagnosed with a primary colorectal tumor and liver metastases 
at the same time or within 6 months, a high TKTL1 expression 
serves as a negative prognostic marker. Yet, if liver metastases 
appear later, this signals a better prognosis. As such, we spec-
ulate that a high TKTL1 expression increases CRC’s invasive-
ness and the metastatic ability. When patients have a high 
expression in their primary tumors but no synchronous metas-
tases, however, there may be some other factor that strongly 
diminishes the cancer’s metastatic ability.
The strengths of our study lie in the unique material con-
sisting of tissue samples of both the primary colorectal tumors 
and corresponding liver metastases and a long follow-up time. 
Yet, the patient material is quite small, and the subgroups of 
patients with synchronous and metachronous disease are even 
smaller. Information concerning the possible neoadjuvant and 
adjuvant therapies was not available for all patients, and the 
subgroups of patients with different treatments or no treatment 
were so small that we were not able to estimate the effect of 
possible chemotherapy on either TKTL1 expression or survival 
reliably. However, in the subgroups of patients with synchro-
nous or metachronous disease, nearly all patients had received 
neoadjuvant and/or adjuvant chemotherapy. In addition, we 
did not have information concerning the patients’ RAS and 
BRAF mutation status or the mismatch repair (MMR) protein 
status of the tumors, since these were not routinely analyzed in 
our clinic prior to 2007.14 Future research should examine 
TKTL1 expression and the RAS mutational status in a larger 
material of colorectal tumor samples.
The weakness in immunohistochemistry as a study method 
is that the scoring is always subjective, and the staining scale 
from zero to three is gradual. To maximize objectivity and to 
validate the scoring, we used two researchers who indepen-
dently scored the staining pattern of the tissue samples, and we 
scored three samples from each tumor.
In conclusion, it seems that a high TKTL1 expression in the 
primary colorectal tumor in patients with synchronous liver 
metastases signifies a poor prognosis to such an extent that it 
might be reasonable to consider aggressive chemotherapy 
instead of liver resection. In metachronous disease, it remains 
unclear if a high expression alone indicates a better prognosis 
or if it reflects other invasiveness-reducing characteristics that 
we have yet to identify.
Materials and methods
Patients
This study included 111 patients who had both primary color-
ectal tumors and liver metastases operated on at Helsinki 
University Hospital between September 1988 and July 2007. 
The primary colorectal tumors were operated on between 1988 
and 2007, and the liver metastases between 1997 and 2007. 
Tissue samples of both the primary tumors and liver metastases 
were obtained from 60 patients, samples of the primary tumor 
only from 21 patients, and samples of the liver metastases only 
from 30 patients.
The Ethics Committee of the Helsinki University Hospital 
approved the study protocol (Dnro HUS 226/E6/06, extension 
TMK02 §66 17.4.2013). Collection and analysis of tissue sam-
ples were approved by the National Supervisory Authority for 
Welfare and Health (Valvira Dnro 10041/06.01.03.01/2012). 
Clinical data were retrieved from patient records.
Preparation of tissue microarray samples and 
immunohistochemistry
Formalin-fixed and paraffin-embedded tissue samples were 
obtained from the Department of Pathology of the Helsinki 
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University Hospital. For each patient, one tumor sample of the 
primary CRC tumor and another from the liver metastases 
were selected. Representative tumor and healthy tissue areas 
were marked on hematoxylin and eosin slides with assistance 
from an experienced pathologist (JH). Six punches (1 mm in 
diameter) were taken from each sample’s tumor area, when 
possible from the invasion-front areas. The tissue microarray 
(TMA) blocks were constructed using a TMA Grand Master 
3D instrument (Histech Ltd Budapest, Hungary). Two series of 
blocks were constructed, each containing three tumor samples 
from each patient’s 1) colorectal tumor blocks and 2) liver 
metastasis blocks.
From the TMA blocks 4-µm-thick sections were cut, fixed 
on to slides, and dried for 12 to 24 h at 37°C. Sections were 
subsequently deparaffinized in xylene and rehydrated through 
graded ethanol and distilled water. For antigen retrieval, the 
slides were treated with Tris-HCl (pH 8.5) in a PreTreatment 
module (LabVision Corp.) for 20 min at 98°C. Staining of 
sections took place in an Autostainer 480 (LabVision) with 
an anti-human TKTL1 antibody (Rida Pentocheck IHC, 
Clone JFC12T10, R-Biopharm AG) diluted to 1:200 with 
Dako REAL Antibody Diluent S2022 (Dako). The primary 
antibody was kept on glass overnight (O/N) followed by a 30- 
min incubation with the secondary peroxide-conjugated rab-
bit/mouse ENV (K5007) Dako REAL Envision/HRP antibody 
(Dako). Finally, the slides were visualized with Dako REAL 
DAB + Chromogen kept on glass for 10 min. Between each step 
of the staining procedure, slides were washed with PBS 0.04% 
Tween20. The slides were counterstained with Meyer’s hema-
toxylin, washed in tap water for 10 min, and finally mounted in 
an aqueous mounting medium (Aquamount, BHD). We used 
a gastric and a colon cancer specimen known to be positive for 
TKTL1 as the positive control in each staining.
Scoring
The immunohistochemically stained tumor samples were 
scored independently by KA and JH using no clinical data or 
information. In liver tissue, TKTL1 staining was visible in 
epithelial cells, but also in the stroma and inflammatory cells. 
The cytoplasmic positivity of the epithelial tumor cells was 
scored on a four-grade scale, where the absence of staining 
was scored as 0, mild staining as 1, moderate staining as 2, and 
strong staining as 3 (Figure 4). The highest score was selected 
to represent the tumor. Samples with no tumor tissue or with 
too few cells for adequate judging were excluded. Samples 
receiving different scores from the two researchers were ree-
valuated until consensus was reached.
Statistical analyses
We used SPSS Statistics 25 (SPSS Inc., Chicago, IL, USA) for all 
statistical analyses and to create the figures. We considered 
P < .05 as statistically significant, and a statistical trend was 
defined as P < .1. DFS and OS were calculated from the date of 
each patient’s first liver resection. DFS was defined as the time 
to any recurrence of CRC or death from any cause. OS was 
calculated until death from any cause. Follow-up data were 
available for all patients, and we set the data cutoff date as 
October 31, 2017.
Survival curves were created using the Kaplan-Meier 
method, and the differences between groups were assessed 
using the log-rank test. The survival analyses were also 
carried out using the Cox proportional hazards model. For 
these analyses, tumor samples with negative, mild or mod-
erate TKTL1 expressions were grouped as “low” and those 
with a strong expression as “high”. The correlations between 
the immunohistochemical expression and clinicopathological 
variables were calculated using the Spearman’s correlation 
test.
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